All In MedTech

Device Trial Radar · NCT01600443

Comparison of Microtrauma in Urethra After Usage of Different Catheters

A Randomized Cross-over Study on Urethral Microtrauma After Intermittent Catheterization.

Last checked: Nov 19, 2026Latest source record: Feb 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

21

Actual

Start

Apr 2012

Primary completion

May 2012

Study completion May 2012

Sponsor

Lead sponsor
Wellspect HealthCareNot on our public-company list
Sponsor type
Industry
First posted
May 17, 2012

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study is undertaken to investigate if the urethral microtrauma, caused by intermittent catheterization, differs between three hydrophilic catheters for intermittent catheterization, LoFric; SpeediCath (SC) and SpeediCath Compact Male (SCCM). The study is a prospective, randomised, cross-over, single-centre study. Each subject will be randomized to use three different catheter types. Three catheterizations will be performed with each catheter type during one day, with at least two hours between each catheterization. The washout period between catheter switch will be at least one week. The primary objective is to evaluate urethral microtrauma for three hydrophilic catheters with regards to hematuria after intermittent catheterization. The secondary objectives are to evaluate urethral microtrauma for three hydrophilic catheters with regards to pyuria and subjective evaluation after intermittent catheterization. The safety of the three catheters will be evaluated in terms of adverse advents, non-serious and serious, rated for causality. The hypothesis that level of hematuria is equal after using different catheters will be tested using Wilcoxon signed rank test. The hypothesis will be rejected if the p-value is less than 5%.

Conditions

  • Hematuria

Interventions

  • LoFricDevice

    Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.

  • SpeediCathDevice

    Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.

  • SpeediCath Compact MaleDevice

    Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HematuriaTime frame: Approximately 2 hours after last catheterization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Unit, R&D Centre Skåne, Skåne University Hospital

    Lund, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.